<DOC>
	<DOCNO>NCT02014844</DOCNO>
	<brief_summary>This pilot study determine efficacy safety aldoxorubicin subject glioblastoma progress follow surgery prior treatment .</brief_summary>
	<brief_title>Phase 2 Study Investigate Efficacy Safety Aldoxorubicin Subjects With Glioblastoma</brief_title>
	<detailed_description>This second line open-labeled pilot phase 2 study subject glioblastoma whose tumor progress follow prior treatment surgery , radiation Temozolomide . Patients receive avastin second-line treatment eligible study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Age 18 year old ; male female 2 . Histologically cytologically confirm unresectable GBM . Subjects recurrent disease whose prior pathology demonstrate GBM need rebiopsied . Subjects prior lowgrade glioma anaplastic glioma eligible histological assessment demonstrate transformation GBM . 3 . Cancer progression treatment follow : surgery , radiation therapy temozolomide first line treatment therapy prior tumor recurrence . 1 . Radiographic progression RANO Working Group Criteria confirm Imaging Endpoints , central image vendor . 2 . By tumor biopsy conduct within 4 week randomization . 4 . An interval least 12 week last dose radiation temozolomide require , unless cancer progression proven diagnostic tumor biopsy . If temozolomide use maintenance phase , must 28day washout period prior Randomization . 5 . Stable decrease dose corticosteroid least 7 day prior randomization . 6 . Capable provide informed consent comply trial procedure . 7 . Karnofsky Performance Status 70 . 8 . ECOG performance status 02 . 9 . Life expectancy 8 week . 10 . Measurable tumor lesion accord RANO work Group Criteria . . In case `` nonmeasurable '' disease due radical surgical resection screening , subject still qualify Inclusion # 3 ( b ) meet . 11 . Women must able become pregnant duration study . 12 . Women childbearing potential must negative serum urine pregnancy test Screening Visit nonlactating . 13 . Geographically accessible site , i.e . ability come study site schedule appointment evaluation . 1 . Prior exposure anthracycline . 2 . Any therapeutic regimen treatment recurrent tumor first line treatment surgery , radiation temozolomide . 3 . Prior treatment bevacizumab experimental antiangiogenic agent . 4 . Palliative surgery and/or radiation treatment le 4 week randomization . 5 . Exposure investigational agent within 30 day Randomization . 6 . History malignancy ( except cure basal cell carcinoma , superficial bladder cancer carcinoma situ cervix ) unless document free cancer 3 year . 7 . Laboratory value : screen serum creatinine &gt; 1.5xULN , ALT &gt; 2.5xULN , total bilirubin &gt; 1.5xULN , ANC &lt; 1500/mm3 , platelet concentration &lt; 100,000/mm3 , absolute lymphocyte count &lt; 1000/mm3 , hematocrit level &lt; 27 % female &lt; 30 % male , serum albumin ≤ 2.5 g/dL , PT/INR 1.5xULN &gt; 3xULN anticoagulant evidence active bleeding . 8 . Evidence CNS hemorrhage CTCAE ≥ grade 2 baseline MRI . 9 . Clinically evident congestive heart failure &gt; class II NYHA guideline . 10 . Current , serious , clinically significant cardiac arrhythmia , define existence absolute arrhythmia ventricular arrythmias classify Lown III , IV V. 11 . History sign active coronary artery disease without angina pectoris . 12 . Serious myocardial dysfunction define ultrasounddetermined LVEF &lt; 45 % predict institutional normal value . 13 . Baseline ATc &gt; 470 msec and/or previous history QT prolongation . 14 . Active , clinically significant serious infection require treatment antibiotic , antiviral , antifungal . 15 . History HIV infection . 16 . Major surgery , except diagnostic tumor biopsy , within 4 week randomization . 17 . Any condition might interfere subject 's participation study evaluation study result . 18 . Any condition unstable could jeopardize subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>glioblastoma</keyword>
	<keyword>aldoxorubicin</keyword>
	<keyword>temozolomide</keyword>
	<keyword>brain cancer</keyword>
	<keyword>brain tumor</keyword>
</DOC>